Premium
Treatment of Advanced Renal Cell Carcinoma with a Combination of Human Lymphoblastoid Interferon–Alpha and Cimetidine
Author(s) -
Kinouchi Toshiaki,
Meguro Norio,
Maeda Osamu,
Saiki Shigeru,
Kuroda Masao,
Usami Michiyuki,
Kotake Toshihiko
Publication year - 1996
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.1996.tb00083.x
Subject(s) - medicine , cimetidine , renal cell carcinoma , alpha interferon , lymphoblast , interferon , interferon alfa , gastroenterology , combination therapy , carcinoma , alpha (finance) , complete response , progressive disease , disease , chemotherapy , oncology , immunology , surgery , cell culture , biology , genetics , construct validity , patient satisfaction
Human lymphoblastoid interferon (IFN)–alpha was administered intramuscularly at doses of 5 megaunits/day 5 to 7 days a week to 32 advanced renal cell carcinoma patients. To augment the antitumor effect of IFN, cimetidine was also administered orally in doses oi 800 mg/day. This combination therapy resulted in a complete response (CR) in 6 patients (19%), a partial response (PR) in 7 (22%), a stable disease (SD) in 11 (34%), and a progressive disease (PD) in 8 (25%). The response rate (CR+PR) was 41%. The pulmonary metastases were more receptive to IFN therapy than those at other sites. The median times to response were 2 months for PR, and 4.5 months for CR. The survival of the responder patients was significantly longer than the nonresponder patients. These results suggest that IFN–alpha and cimetidine combination therapy may be of use in the management of advanced renal cell carcinoma.